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Abstract
Sex hormones not only regulate the gonads function, but also may affect the cardiovascular system, although their 
role is still not clear. Testosterone influence on arterial pressure and left ventricular hypertrophy were widely reported. 
A number of factors have been implicated as the underlying cause of the relation between testosterone and blood 
pressure, including sex and age as most important ones. In present findings, a 24-hour ABPM revealed that 33.9% of 
patients had an altered pattern of blood pressure with no significant differences between sexes. In the whole studied 
sample, positive correlation has been found between testosterone and 24-hour systolic blood pressure, daytime BP, 
sodium and potassium levels in the 24-hour urine collection, and left ventricular mass index. In conclusion, testos-
terone association with blood pressure profile and left ventricular mass in a young hypertensive population seems to 
be probable, but further analysis is necessary.
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Introduction
Sex hormones not only regulate the gonads’ func-
tion but also may affect the cardiovascular system, 
although their role is still not clear [1–5]. 
Referring to the testosterone influence on arterial 
pressure, literature has known many mechanisms of 
which androgen-dependent gender differences were 
widely reported [3, 6]. Similarly, the relationship 
between testosterone levels and an unfavourable BP 
response for testosterone chronic supplementation 
driven by activation of renin-angiotensin system 
(RAS) [7, 8].
Since declining gonadal function with aging is 
known, age need be taken into account to examine 
the relationship between testosterone and blood pres-
sure [9, 10]. The results of previous studies performed 
in elderly and middle-aged patients indicate the asso-
ciation between testosterone levels and hypertension 
[1, 3, 9, 11]. Data in the young population are 
inadequate. The aim of this study was to explore the 
relationship between testosterone and blood pressure 
profile in young hypertensive patients. 
Materials and methods
Study population
The study was carried out among patients with es-
tablished diagnosis of essential hypertension treated 
at university-affiliated Department of Hypertension 
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and Internal Medicine in Szczecin. Overall, we in-
cluded 80 consecutive hypertensive patients (35 fe-
males, 45 males), mean age 29.9 ± 16.3 years. We ex-
cluded those patients who were treated with spirono-
lactone, glucocorticoids, anabolic steroids, and oral 
contraception. We also evaluated 24-hour urinary 
potassium (normal range: 25−125 mmol/24h) and 
sodium (normal range: 40−220 mmol/24h) excre-
tion. Based on medical history and medical records, 
we collected data on family cardiovascular burden, 
smoking habits, dyslipidaemia, chronic kidney dis-
ease, and type 2 diabetes.
Measurements
Anthropometric measurements were taken and body 
mass index (BMI) was calculated from the body 
weight and height. In all cases, we performed 24-
hour blood pressure monitoring (ABPM) (Spacelabs 
Healthcare) and analysed 24-hour daytime and noc-
turnal systolic, diastolic, and mean blood pressure. 
Testosterone (normal range for men: 4.25−30.37 
pg/ml; normal range for women: 0.04−4.18 pg/
ml), PRA (normal range: 0.51−2.64 ng/ml/h) and 
plasma aldosterone (normal range: 10−160 pg/ml) 
were measured using commercially available assays. 
From these measurements we calculated the aldo-
sterone-to-renin ratio (ARR). In reference to the 
current guidelines, the left ventricular mass index 
has been assessed in all cases [12]. Echocardiography 
was performed by using a GE Vivid S6 device [12]. 
Statistical analysis
Descriptive data are presented as mean ± SD or 
numbers and percentage. When comparing normal-
ly distributed variables between groups of men and 
women, an independent t test was used for com-
paring means. For comparison of skewedly distrib-
uted variables between the study groups, median 
values were calculated and Mann-Whitney U  and/
or Kruskal-Wallis test was used. Categorical vari-
ables were evaluated by Chi square test. Correla-
tions between the study variables were evaluated by 
Spearman’s  rank correlation. P values < 0.05 were 
considered significant. All analyses were carried out 
in Statistica version 12 (Statsoft, Poland).
Results
The main clinical and biochemical characteristics 
of the study sample are shown in Tables I–IV. Ma-
jority of subjects were overweight/obese. As many 
as 82.5% of patients had a  positive family history 
of cardiovascular disease. Additionally, 42.3% were 
smokers. A 24-hour ABPM revealed that 33.9% of 
patients had an altered pattern of blood pressure 
(non-dipping, reverse-dipping, or extreme-dipping) 
with no significant differences between sexes. In the 
whole studied sample, positive correlation has been 
Table I. Baseline clinical characteristics of the study population 
(n = 80) 
Mean value ( ± SD)
Median (range)
Age (years) 29.9 ± 16.3
30 (19.0−43.0)
BMI [kg/m2] 28.6 ± 6.2
27.5 (19.4−48.0)
Duration of hypertension (months) 45.6 ± 57.3
24.0 (1.0−308.0)
SBP [mm Hg] 148.3 ± 16.3
148 (114.0−190.0)
DBP [mm Hg] 109.9 ± 12.4
90 (62.0−130.0)
MAP [mm Hg] 109.9 ± 12.0
109.5 (83.3−146.7)
% (n)
Women 43.7% (35)
Men 56.3% (45)
Smokers 42.3% (44)
Family CVD history 82.5% (66)
BMI < 25 kg/m2 27.5% (22)
BMI ≥ 25 < 30kg/m2 41.3% (33)
BMI ≥ 30kg/m2 31.2% (25)
SD — standard deviation; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic 
blood pressure; MAP — mean arterial pressure
Table II. Selected echocardiographic parameters of the study 
population (n = 80)
Mean ( ± SD)
Median (range)
LVMI [g/m2] 81.3 ± 19.5
79.2 (18.7−136.7)
RWT 0.5 ± 1.9
0.3 (0.2−17.2)
Septal velocity [cm/s] 12.3 ± 3.1
12.0 (5.3−20.0)
Lateral velocity [cm/s] 15.6 ± 3.4
15.3 (8.0−25.0)
LAVI [ml/m2] 18.6 ± 9.1
17.1 (2.4−87.4)
E/e’ Ratio 5.9 ± 2.2
5.7 (1.2−19.9)
LVMI — left ventricular mass index; RWT — relative wall thickness; E — early mitral inflow velocity; 
e’ — mitral annular early diastolic velocity; LAVI — left atrium volume index
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Table III. Biochemical and hormonal characteristics of study po-
pulation (n = 80)
Mean ( ± SD)
Median (range)
Serum sodium level [mmol/l] 141.0 ± 1.8
141.0 (136.0−145.0)
Serum potassium level [mmol/l] 4.4 ± 0.3
4.4 (3.7−5.1)
Sodium in 24h urine collection 
[mmol/24h]
183.7 ± 62.5
175.2 (73.0−361)
Potassium in 24h urine collection 
[mmol/24h]
54.0 ± 20.2
50.7 (17.0−141.0)
PRA [ng/ml/h] 1.5 ± 0.6
1.5 (0.6–3.2)
Aldosterone [pg/ml] 105.7 ± 36.5
108.0 (31.0–178.0)
ARR 7.1 ± 2.7
7.0 (1.4–17.2)
Testosterone [pg/ml] 10.4 ± 11.4
7.5 (0.6–70.2)
PRA — plasma renin activity; ARR — aldosterone/renin ratio 
Table IV. 24-hour ambulatory blood pressure monitoring parame-
ters in study population (n = 80)
Mean ± SD
Median (range)
24 SBP [mm Hg] 126.2 ± 10.5
126.5 (102.0–177.0)
24 DBP [mm Hg] 75.9 ± 8.3
75.5 (53.0–109.0)
24 MAP [mm Hg] 92.2 ± 8.1
91.0 (76.0–132.0)
SBPd [mm Hg] 132.5 ± 12.1
129.0 (105.0–181.0)
DBPd [mm Hg] 78.7 ± 8.4
79.0 (54.0–111.0)
MAPd [mm Hg] 94.4 ± 12.8
94.0 (46.0–144.0)
SBPn [mm Hg] 114.9 ± 12.8
116.0 (80.0–140.0)
DBPn [mm Hg] 68.6 ± 10.5
67.0 (51.0–125.0)
MAPn [mm Hg] 83.0 ± 11.5
84.0 (42.0–121.0)
% (n)
Dippers 66.1% (53)
Non-dippers 31.3 (25)
Reverse-dippers 1.3% (1)
Extreme-dippers 1.3% (1)
24 SBP — 24-hour systolic blood pressure; 24 DBP — 24-hour diastolic blood pressure; 24 MAP — 
24-hour mean arterial pressure; SBPd — daytime systolic blood pressure; DBPd — daytime diastolic 
blood pressure; MAPd — daytime mean arterial pressure; SBPn — nocturnal systolic blood pressure; 
DBPn — nocturnal diastolic blood pressure; MAPn — nocturnal mean arterial pressure
found between testosterone and 24-hour systolic 
blood pressure, daytime BP, sodium and potassium 
levels in the 24-hour urine collection, and left ven-
tricular mass index (Table V). There was only weak 
negative correlation between total testosterone (TT) 
and nocturnal diastolic blood pressure (p ≤ 0.02). 
Compared with female, men had significantly high-
er testosterone level, 24-hour and daytime systolic 
blood pressure and lower nocturnal diastolic blood 
pressure (Table VI). Testosterone level was inversely 
correlated with age. We did not found significant as-
sociation between TT and non- dipping profile after 
adjusting for age. 
Discussion
In the past decades, the associations between egzo- 
and endogenous testosterone (TT) and blood pres-
sure (BP) in males and females have been extensive-
ly studied; however, inconsistent results have been 
obtained. In the present findings a 24-hour ABPM 
revealed that 33.9% of patients had an altered pat-
tern of blood pressure (non-dipping, reverse-dipping, 
or extreme-dipping) with no significant differences 
between sexes. A positive correlation has been found 
between testosterone and 24-hour systolic blood 
pressure, daytime BP. This findings are in line with 
the general research trend [1, 11, 13, 14]. Litera-
ture suggests various mechanisms involved in the 
testosterone impact on blood pressure regulation. 
In animal models, chronic testosterone supplements 
caused hypertension in male spontaneously hyper-
tensive rats (SHR) and this unfavourable BP response 
was mainly driven by activation of renin-angiotensin 
system (RAS) [7]. In addition, prenatal testosterone 
exposure in female rats resulted in increased serum 
vasopressin and angiotensin II concentrations, lead-
ing to the development of hypertension [8], while 
a chronic blockade of RAS with enalapril abolished 
age-dependent changes in BP [15], suggesting that 
the RAS promotes oxidative stress leading to pro-
duction of vasoconstrictor substances and reduction 
in nitric oxide availability. In our study, we have not 
observed any relationship between TT and RAS, but 
it may be due to small sample size.
Salt-sensitivity of blood pressure has been sug-
gested as a result of the interaction of many genetic 
and environmental factors [16]. In recent years tes-
tosterone-dependent pressure-natriuresis relation-
ship has been highlighted [3, 6, 17, 18]. According 
to these data, we have shown a positive correlation 
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Table V. Correlations between testosterone serum level and selected parameters
Variables R P-value
Testosterone
[pg/ml]
Age (years) –0.25 p < 0.03
BMI [kg/m2] –0.05 ns
Duration of hypertension (months) 0.16 ns
24 SBP [mm Hg] 0.22 p < 0.05
24 DBP [mm Hg] –0.20 ns
24 MAP [mm Hg –0.01 ns
SBPd [mm Hg] 0.23 p < 0.04
DBPd [mm Hg] –0.01 ns
MAPd [mm Hg] –0.16 ns
SBPn [mm Hg] 0.04 ns
DBPn [mm Hg] –0.28 p < 0.02
MAPn [mm Hg] –0.16 ns
Sodium in 24h urine collection [mmol/24h] 0.26 p < 0.03
Potassium in 24h urine collection [mmol/24h] 0.25 p < 0.03
PRA [ng/ml/h] –0.02 ns
Aldosterone [pg/ml] –0.06 ns
ARR –0.21 ns
LVdMI [g/m2] 0.26 p < 0.03
RWT 0.15 ns
Septal velocity [cm/s] –0.14 ns
Lateral velocity [cm/s] –0.06 ns
LAVI [ml/m2] –0.07 ns
E/e’ Ratio 0.01 ns
R — Spearman rank correlation coefficient; ns — no statistical significance
Table VI. Comparison of selected parameters among women and men groups
Women
(n = 35)
Men
(n = 45)
P-value
Age (years) 30.3 ± 7.3 29.5 ± 10.1 ns
BMI [kg/m2] 28.3 ± 6.0 28.8 ± 6.4 ns
Testosterone [pg/ml] 3.8 ± 3.2 15.5 ± 10.1 p < 0.0001
24 SBP [mm Hg] 122.7 ± 9.9 130.0 ± 10.1 p < 0.05
24 DBP [mm Hg] 77.1 ± 8.5 75.0 ± 8.1 ns
24 MAP [mm Hg] 91.9 ± 8.5 92.4 ± 7.8 ns
SBPd [mm Hg] 127.4 ± 13.1 132.9 ± 10.8 p < 0.005
DBPd [mm Hg] 79.9 ± 8.0 77.9 ± 8.8 ns
MAPd [mm Hg] 94.9 ± 15.3 94.2 ± 10.6 ns
SBPn [mm Hg] 114.8 ± 12.1 115.0 ± 7.7 ns
DBPn [mm Hg] 71.9 ± 13.3 66.1 ± 6.8 p < 0.02
MAPn [mm Hg] 83.6 ± 13.4 82.6 ± 9.9 ns
Dippers 54.3% (19) 76.0% (34) ns
Non-dippers 45.1 (15) 24.0% (11) ns
Reverse-dippers 0.9% (1) 0% (0) ns
24 SBP — 24-hour systolic blood pressure; 24 DBP — 24-hour diastolic blood pressure; 24 MAP — 24-hour mean arterial pressure; SBPd — daytime systolic blood pressure; DBPd — daytime diastolic blood pressure; 
MAPd — daytime mean arterial pressure; SBPn — nocturnal systolic blood pressure; DBPn — nocturnal diastolic blood pressure; MAPn — nocturnal mean arterial pressure
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between TT and sodium excretion in 24-hour urine 
collection.
Some studies examining the relationship between 
TT and blood pressure suggest that BP increase is 
secondary to obesity and insulin resistance [19–21]. 
However, in contrast to these opinion, other studies 
demonstrated that independently of food intake and 
weight gain, hyperandrogenaemia did not exacer-
bate hypertension in female SHR [22]. Because the 
majority of our respondents were overweight/ obese, 
further studies are needed to assess this relationship. 
A number of factors have been implicated as the 
underlying cause of the relation between testoster-
one and blood pressure, including sex and age as 
most important ones. Our findings showed that 
testosterone level was inversely correlated with age. 
Compared with female, men had significantly high-
er testosterone level, 24-hour and daytime systolic 
blood pressure and lower nocturnal diastolic blood 
pressure. We did not found significant association 
between TT and altered BP profile after adjusting 
for age. 
The influence of sex hormones on the cardiovas-
cular system at least partially explains the occurrence 
of sex-dependent epidemiological differences in the 
incidence of hypertension among men and women. 
In early human studies performed in men, a  step-
wise decrease in mean systolic and diastolic BP per 
increasing quartile of testosterone was shown [14], 
suggesting a  linear relationship between circulating 
hormone level and BP. However, in the recent study 
carried out in healthy men aged 20–50 years, changes 
in BP did not appear to be regulated by testosterone 
levels [23]. Moreover, in hypogonadal elderly men, 
long-term testosterone therapy was associated with 
a significant decrease in systolic and diastolic BP [24]. 
As showed the findings from the NHANES III study, 
men generally have a  higher pressure than women 
through middle age [25]. This difference is clear 
until women reach menopause and the lack of hy-
potensive effect of hormone replacement therapy in-
dicates oestrogen-independent mechanism [26, 27]. 
Ziemens et al. in the longitudinal women-popula-
tion-based study demonstrated a positive association 
between total testosterone and the incidence of hy-
pertension [13]. It also has been suggested that free 
androgen index might be a robust biomarker of the 
transition to new onset hypertension and higher BP 
category in postmenopausal women [28]. The im-
pact of testosterone on blood pressure seems to be 
confirmed by the fact that women with polycystic 
ovary syndrome or virilising tumours are frequently 
diagnosed with hypertension [29–31]. On the other 
hand, some studies showed no association between 
testosterone level and BP in peri- and postmenopaus-
al period [32, 33]. 
In reference to the current guidelines, the assess-
ment of organ damage, including left ventricular 
mass index, is important to stratify cardiovascular 
risk in patients with hypertension [12]. Since the 
relationship between anabolic steroids abuse and 
sudden cardiac death was observed, many studies 
have reported an association between testosterone 
and ventricular hypertrophy [34]. It has been prov-
en that testosterone affect the cardiomyocytes pro-
liferation and promotes cardiac hypertrophy [35]. 
Consistently, an inverse association between testos-
terone concentration and central systolic BP (major 
determinant of left ventricular hypertrophy [LVH]) 
was reported [36]. Being in line with the majority 
of reports [37], the current study showed a positive 
correlation between TT and left ventricular mass 
index. Opposite to this findings, Gyllenborg et al. 
has found no association between testosterone levels 
and LVH [38].
In conclusion, testosterone association with blood 
pressure profile and left ventricular mass in a young 
hypertensive population seems to be probable but 
further analysis is necessary.
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